Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer
NCT01526486 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 29
Last updated 2015-05-06
Summary
Patients with melanoma, some other rare skin cancers, and some cancers of the penis and scrotum can have their cancer spread to the lymph nodes in the upper part of the leg, called the groin. Medically, this area is called the inguinal area. At present, for melanomas and skin cancers this type of spread is usually found with a special test called a "sentinel lymph node biopsy". This procedure can find spread of even a few cells in a single lymph node-allowing the treating doctor to find the spread very early.
Treatment for patients with skin cancer in the lymph nodes in this area is to remove all of the lymph nodes in this area. In patients with cancers of the penis and scrotum who do hot have any evidence of cancer having spread either by physical examination or by radiology tests, the lymph nodes in this area are removed to check and see if there is cancer in them. This is called staging.
At present, the standard way to remove all of the lymph nodes in the groin is by a large incision, approximately 8-10 inches in length. For patients who have this operation, there is a very high incidence of infection after surgery: as many as 50% as patients can have a problem after surgery. These infections range from a low grade skin infection needing oral antibiotics to deep infections requiring the wound to be opened and occasionally needing readmission to the hospital and antibiotics given via the vein.
With the advent of new technology and new equipment, the ability to perform this procedure through small incisions away from the groin and further down the leg has become possible. This procedure has never been performed routinely nor compared side by side to the standard open approach. The investigators propose to perform this protocol in two phases.
The investigators have performed procedures in 20 groins to this point and have confirmed the number of lymph nodes and visually verified that the procedure is identical to the open procedure. The investigators performed these procedures in order to insure that the investigators were offering an equivalent option regardless of which procedure the patient is randomized to.
The study will involve the randomization of patients undergoing the procedure. The investigators will randomize the next 110 patients in a 2:1 fashion (two people will get the videoscopic procedure for every one who gets the open procedure) until 73 patients are included in the video arm and 37 in the open arm. Outcomes including recurrence rate, duration of drain requirements, and incidence of lymphedema will be followed. Patients will be followed using standard of care processes, including regular office visits, physical exams, and radiographic imaging, when indicated. Patients will be followed for 5 years.
Conditions
- Melanoma
- Merkel Cell Carcinoma
- Squamous Cell Carcinoma
- Penile Carcinoma
- Urethral Carcinoma
- Extramammary Paget's Disease
- Scrotal Carcinoma
- Anal Cancer
- Vulvar Cancer
- Skin Cancer
- Lymphadenopathy
Interventions
- PROCEDURE
-
Videoscopic procedure
Minimally invasive, three port approach, (using a laparoscope to perform a procedure previously performed through open surgery).
- PROCEDURE
-
Open, traditional approach
Open surgical procedure, with sartorius muscle transfer.
Sponsors & Collaborators
-
Emory University
lead OTHER
Principal Investigators
-
Keith Delman, MD · Emory University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-06-30
- Primary Completion
- 2013-02-28
- Completion
- 2013-02-28
Countries
- United States
Study Locations
More Related Trials
-
Omitting Therapeutic Lymph Node Dissection in Patients With Melanoma (Stage 3) and Major Pathological Response in the Index Lymph Node
NCT06754904 ·Status: RECRUITING ·Phase: NA
-
Early Complications After Axillary and Inguinal Lymph Node Dissection in Stage III Melanoma Patients
NCT04680182 ·Status: COMPLETED ·Phase: NA
-
Evaluation Of Mobile Gamma Camera Imaging For Sentinel Node Biopsy In Melanoma
NCT01531608 ·Status: COMPLETED
-
A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma
NCT04708418 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma
NCT01264731 ·Status: COMPLETED ·Phase: PHASE1
-
PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma
NCT00004152 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma
NCT03698019 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Neoadjuvant Combination Immunotherapy for Stage III Melanoma
NCT03842943 ·Status: RECRUITING ·Phase: PHASE2
-
One-year Recurrence-free Survival of Melanoma Patients Eligible for a Sentinel Lymph Node Biopsy
NCT06809491 ·Status: ACTIVE_NOT_RECRUITING
-
Neoadjuvant and Adjuvant Checkpoint Blockade
NCT02519322 ·Status: COMPLETED ·Phase: PHASE2
-
Defining the Role of the Skin Microbiome in Immune-related Adverse Events
NCT04734704 ·Status: UNKNOWN ·Phase: NA
-
Complete Lymph Node Dissection vs Watchful Waiting in Patients With Malignant Melanoma (Thickness of 1,0mm+ and Evidence of Metastases in the Sentinel Node)
NCT02434107 ·Status: COMPLETED ·Phase: NA
-
High-resolution Magnetic Resonance Imaging (MRI) Scans to Look for Spread of Melanoma to Nearby Lymph Nodes
NCT00463892 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Avoidance of Futile Excisions Through Skin Tele-triage
NCT05982600 ·Status: COMPLETED
-
Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery
NCT01886235 ·Status: COMPLETED ·Phase: NA
-
Cryoablation+Ipilimumab+Nivolumab in Melanoma
NCT05779423 ·Status: RECRUITING ·Phase: PHASE2
-
Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
NCT06568172 ·Status: SUSPENDED ·Phase: PHASE3
-
Multicenter Selective Lymphadenectomy Trial (MSLT)
NCT00275496 ·Status: COMPLETED ·Phase: PHASE3
-
Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer
NCT04428671 ·Status: RECRUITING ·Phase: PHASE1
-
The Multicentre Selective Lymphadenectomy Trial - 3
NCT07049276 ·Status: RECRUITING ·Phase: NA
-
mRNA Electroporated Autologous Dendritic Cells for Stage III/IV Melanoma
NCT01676779 ·Status: COMPLETED ·Phase: PHASE2
-
SWOG-9430: Surgery in Treating Patients With Metastatic Melanoma
NCT00002860 ·Status: COMPLETED ·Phase: PHASE2
-
Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma
NCT03276832 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma
NCT01531244 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Fluorescein for Lymphatic Mapping and Sentinel Lymph Node (SLN) Biopsy in Patients With Stage I and II Malignant Melanoma
NCT00847522 ·Status: COMPLETED ·Phase: PHASE1/PHASE2